Why the study?
Does CYP2C19 loss-of-function genotype increase the risk of in-stent restenosis in patients treated with vertebral artery stents?
Population
90 patients treated with vertebral artery stent between 2004 and 2011 at a single center in Nanjing, China.
Comparison
CYP2C19 loss-of-function genotype vs CYP2C19 wild-type genotype (wt/wt alleles)
Design
Cohort
Follow-up
54 months
Authors
Loading...
CYP2C19 loss-of-function genotype was associated with higher ISR risk after vertebral stenting; leaves open whether genotyping should guide antiplatelet therapy.
Does CYP2C19 loss-of-function genotype increase the risk of in-stent restenosis in patients treated with vertebral artery stents?
CYP2C19 loss-of-function genotype and hyperlipidemia are significant risk factors for in-stent restenosis and recurrent stroke in patients undergoing vertebral artery stenting.
Lin et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: